DMD and myositis disease: In myositis and Becker muscular dystrophy, the inflammatory marker miR-146b is known to down-regulate dystrophin expression, whereas the reduction of miR-146b via anti-inflammatory drugs or via miRNA-targeting oligos is proposed as a method to increase dystrophin levels to help improve muscle health [30,31].